-
1
-
-
34248379222
-
Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database
-
Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-763.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 754-763
-
-
Walker, U.A.1
Tyndall, A.2
Czirják, L.3
-
2
-
-
0036124419
-
Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIRGSSSc)
-
Ferri C, Valentini G, Cozzi F, et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIRGSSSc). Medicine (Baltimore) 2002; 81: 139-153.
-
(2002)
Medicine (Baltimore)
, vol.81
, pp. 139-153
-
-
Ferri, C.1
Valentini, G.2
Cozzi, F.3
-
3
-
-
0028360565
-
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
-
Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149: 1583-1590.
-
(1994)
Am J Respir Crit Care Med
, vol.149
, pp. 1583-1590
-
-
Wells, A.U.1
Cullinan, P.2
Hansell, D.M.3
-
4
-
-
0028130596
-
Severe restrictive lung disease in systemic sclerosis
-
Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-1289.
-
(1994)
Arthritis Rheum
, vol.37
, pp. 1283-1289
-
-
Steen, V.D.1
Conte, C.2
Owens, G.R.3
-
5
-
-
33745227399
-
Cyclophosphamide versus placebo in scleroderma lung disease
-
Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
-
(2006)
N Engl J Med
, vol.354
, pp. 2655-2666
-
-
Tashkin, D.P.1
Elashoff, R.2
Clements, P.J.3
-
6
-
-
36249001195
-
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
-
Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Resp Crit Care Med 2007; 76: 1026-1034.
-
(2007)
Am J Resp Crit Care Med
, vol.76
, pp. 1026-1034
-
-
Tashkin, D.P.1
Elashoff, R.2
Clements, P.J.3
-
7
-
-
33845643063
-
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
-
Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arhtritis Rheum 2006; 54: 3962-3970.
-
(2006)
Arhtritis Rheum
, vol.54
, pp. 3962-3970
-
-
Hoyles, R.K.1
Ellis, R.W.2
Wellsbury, J.3
-
8
-
-
33644870428
-
A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis
-
Nadashkevich O, Davis P, Fritzler M, et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheum 2006; 25: 205-212.
-
(2006)
Clin Rheum
, vol.25
, pp. 205-212
-
-
Nadashkevich, O.1
Davis, P.2
Fritzler, M.3
-
9
-
-
55749093240
-
Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
-
Nannini C, West CP, Erwin PJ, et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arhtritis Res Ther 2008; 10: R124.
-
(2008)
Arhtritis Res Ther
, vol.10
-
-
Nannini, C.1
West, C.P.2
Erwin, P.J.3
-
10
-
-
66149100618
-
European League Against Rheumatism (EULAR) Scleroderma Trials and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: Methods of elaboration and results of systemic literature research
-
Avouac J, Kowal-Bielecka O, Landewé R, et al. European League Against Rheumatism (EULAR) Scleroderma Trials and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systemic literature research. Ann Rheum Dis 2009; 68: 620-628.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 620-628
-
-
Avouac, J.1
Kowal-Bielecka, O.2
Landewé, R.3
-
11
-
-
15644362541
-
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis
-
Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-2198.
-
(1997)
Arthritis Rheum
, vol.40
, pp. 2187-2198
-
-
Guillevin, L.1
Cordier, J.F.2
Lhote, F.3
-
12
-
-
75649109604
-
A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
-
Derk CT, Grace E, Shenin M, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009; 48: 1595-1599.
-
(2009)
Rheumatology
, vol.48
, pp. 1595-1599
-
-
Derk, C.T.1
Grace, E.2
Shenin, M.3
-
13
-
-
79955788963
-
Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis
-
Le EN, Wigely FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70: 1104-1107.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1104-1107
-
-
Le, E.N.1
Wigely, F.M.2
Shah, A.A.3
-
14
-
-
33847394965
-
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis
-
Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology 2007; 46: 442-445.
-
(2007)
Rheumatology
, vol.46
, pp. 442-445
-
-
Nihtyanova, S.I.1
Brough, G.M.2
Black, C.M.3
-
15
-
-
36349014858
-
Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
-
Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Resp Med 2008; 102: 150-155.
-
(2008)
Resp Med
, vol.102
, pp. 150-155
-
-
Zamora, A.C.1
Wolters, P.J.2
Collard, H.R.3
-
16
-
-
80755163187
-
Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
-
Simeó n-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011; 30: 1393-1398.
-
(2011)
Clin Rheumatol
, vol.30
, pp. 1393-1398
-
-
Simeón-Aznar, C.P.1
Fonollosa-Plá, V.2
Tolosa-Vilella, C.3
-
17
-
-
84878676906
-
Enteric-coated mycophenolate sodium for progressive systemic sclerosis a prospective open-label study with CT histography for monitoring of fibrosis
-
Henes JC, Horger M, Amberger C, et al. Enteric-coated mycophenolate sodium for progressive systemic sclerosis a prospective open-label study with CT histography for monitoring of fibrosis. Clin Rheumatol 2013; 32: 673-678.
-
(2013)
Clin Rheumatol
, vol.32
, pp. 673-678
-
-
Henes, J.C.1
Horger, M.2
Amberger, C.3
-
18
-
-
34248137269
-
A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis
-
Vanthuyne M, Blockmans D, Westhovens R, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007; 25: 287-292.
-
(2007)
Clin Exp Rheumatol
, vol.25
, pp. 287-292
-
-
Vanthuyne, M.1
Blockmans, D.2
Westhovens, R.3
-
19
-
-
79952109158
-
Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
-
Koutroumpas A, Ziogas A, Alexiou, et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010; 29: 1167-1168.
-
(2010)
Clin Rheumatol
, vol.29
, pp. 1167-1168
-
-
Koutroumpas, A.1
Ziogas, A.2
Alexiou3
-
20
-
-
39449103902
-
Effect of mycophenolate mofetil on pulmonary function in Sclerodermaassociated interstitial lung disease
-
Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in Sclerodermaassociated interstitial lung disease. Chest 2008; 133: 455-460.
-
(2008)
Chest
, vol.133
, pp. 455-460
-
-
Gerbino, A.J.1
Goss, C.H.2
Molitor, J.A.3
-
21
-
-
33746437403
-
Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease
-
Liossis SNC, Bounas A, Anonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006; 45: 1005-1008.
-
(2006)
Rheumatology
, vol.45
, pp. 1005-1008
-
-
Liossis, S.N.C.1
Bounas, A.2
Anonopoulos, A.P.3
-
22
-
-
84876918697
-
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease
-
Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640-646.
-
(2013)
J Rheumatol
, vol.40
, pp. 640-646
-
-
Fischer, A.1
Brown, K.K.2
du Bois, R.M.3
-
23
-
-
84864095990
-
Treatment of systemic sclerosis complications: What to use when first-line treatment fails-a consensus of systemic sclerosis experts
-
Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42: 42-55.
-
(2012)
Semin Arthritis Rheum
, vol.42
, pp. 42-55
-
-
Walker, K.M.1
Pope, J.2
-
24
-
-
44949238111
-
Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study
-
Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008; 35: 1064-1072.
-
(2008)
J Rheumatol
, vol.35
, pp. 1064-1072
-
-
Bérezné, A.1
Ranque, B.2
Valeyre, D.3
-
25
-
-
34648822788
-
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy
-
Paone C, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007; 25: 613-616.
-
(2007)
Clin Exp Rheumatol
, vol.25
, pp. 613-616
-
-
Paone, C.1
Chiarolanza, I.2
Cuomo, G.3
-
26
-
-
0029867337
-
Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial
-
Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-372.
-
(1996)
Br J Rheumatol
, vol.35
, pp. 364-372
-
-
van den Hoogen, F.H.1
Boerbooms, A.M.2
Swaak, A.J.3
-
27
-
-
0034970031
-
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma
-
Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-1358.
-
(2001)
Arthritis Rheum
, vol.44
, pp. 1351-1358
-
-
Pope, J.E.1
Bellamy, N.2
Seibold, J.R.3
-
28
-
-
0031684342
-
Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis
-
Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-1619.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 1613-1619
-
-
Steen, V.D.1
Medsger Jr., T.A.2
-
29
-
-
37749049969
-
Group Français de Recherche sur le Sclérodermie (GFRS). Mortality and risk factors of scleroderma renal crisis: A French retrospective study of 50 patients
-
Teixeira L, Mouthon L, Mahr A, et al. Group Français de Recherche sur le Sclérodermie (GFRS). Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-116.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 110-116
-
-
Teixeira, L.1
Mouthon, L.2
Mahr, A.3
-
30
-
-
0036845156
-
Predictors and outcomes of scleroderma renal crisis: The high dose versus low-dose of penicillamine in early diffuse systemic sclerosis trial
-
DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high dose versus low-dose of penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-2989.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 2983-2989
-
-
DeMarco, P.J.1
Weisman, M.H.2
Seibold, J.R.3
-
31
-
-
0024465792
-
Normotensive renal failure in systemic sclerosis
-
Helfrich DJ, Banner B, Steen VD, et al. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32: 1128-1134.
-
(1989)
Arthritis Rheum
, vol.32
, pp. 1128-1134
-
-
Helfrich, D.J.1
Banner, B.2
Steen, V.D.3
-
32
-
-
0036225585
-
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis
-
Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-736.
-
(2002)
J Rheumatol
, vol.29
, pp. 731-736
-
-
Giacomelli, R.1
Valentini, G.2
Salsano, F.3
-
33
-
-
33845867399
-
Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: Experience in one centre
-
Beretta L, Caronni M, Raimondi M, et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 2007; 26: 168-172.
-
(2007)
Clin Rheumatol
, vol.26
, pp. 168-172
-
-
Beretta, L.1
Caronni, M.2
Raimondi, M.3
-
34
-
-
0036843172
-
Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function
-
Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371-2378.
-
(2002)
J Rheumatol
, vol.29
, pp. 2371-2378
-
-
Griffiths, B.1
Miles, S.2
Moss, H.3
-
35
-
-
33846333911
-
Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease
-
Yiannopoulos G, Pastromas V, Antonopoulos I, et al. Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007; 27: 357-361.
-
(2007)
Rheumatol Int
, vol.27
, pp. 357-361
-
-
Yiannopoulos, G.1
Pastromas, V.2
Antonopoulos, I.3
-
36
-
-
78649502678
-
Immunotherapy of systemic sclerosis
-
Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy 2010; 2: 863-878.
-
(2010)
Immunotherapy
, vol.2
, pp. 863-878
-
-
Manno, R.1
Boin, F.2
-
37
-
-
34848833579
-
B cell infiltration in systemic sclerosis-associated interstitial lung disease
-
Lafyatis R, O'Hara C, Feghali-Bostwick CA, et al. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007; 56: 3167-3168.
-
(2007)
Arthritis Rheum
, vol.56
, pp. 3167-3168
-
-
Lafyatis, R.1
O'Hara, C.2
Feghali-Bostwick, C.A.3
-
38
-
-
43049159803
-
Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab
-
McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008; 47: 552-553.
-
(2008)
Rheumatology
, vol.47
, pp. 552-553
-
-
McGonagle, D.1
Tan, A.L.2
Madden, J.3
-
39
-
-
77957019831
-
Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature
-
Daoussis D, Liossis SN, Tsamandas AC, et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010; 40: 127-136.
-
(2010)
Semin Arthritis Rheum
, vol.40
, pp. 127-136
-
-
Daoussis, D.1
Liossis, S.N.2
Tsamandas, A.C.3
-
40
-
-
84863300540
-
Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab
-
Yoo WH. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2012; 32: 795-798.
-
(2012)
Rheumatol Int
, vol.32
, pp. 795-798
-
-
Yoo, W.H.1
-
41
-
-
73449095775
-
Rituximab in diffuse cutaneous systemic sclerosis: An open label clinical and histopatological study
-
Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open label clinical and histopatological study. Ann Rheum Dis 2010; 69: 193-197.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 193-197
-
-
Smith, V.1
van Praet, J.T.2
Vandooren, B.3
-
42
-
-
59649109772
-
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
-
Layaftis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60: 578-583.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 578-583
-
-
Layaftis, R.1
Kissin, E.2
York, M.3
-
43
-
-
77950443096
-
Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study
-
Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010; 49: 271-280.
-
(2010)
Rheumatology
, vol.49
, pp. 271-280
-
-
Daoussis, D.1
Liossis, S.N.2
Tsamandas, A.C.3
-
44
-
-
84867383069
-
Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis
-
Daoussis D, Liossis SN, Tsmandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheum 2012; 30: 17-22.
-
(2012)
Clin Exp Rheum
, vol.30
, pp. 17-22
-
-
Daoussis, D.1
Liossis, S.N.2
Tsmandas, A.C.3
-
45
-
-
77956992383
-
B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
-
Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
-
(2010)
Arthritis Res Ther
, vol.12
-
-
Bosello, S.1
de Santis, M.2
Lama, G.3
-
46
-
-
84865814629
-
Severe interstitial lung disease in connective tissue disease: Rituximab as rescue therapy
-
Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40: 641-648.
-
(2012)
Eur Respir J
, vol.40
, pp. 641-648
-
-
Keir, G.J.1
Maher, T.M.2
Hansell, D.M.3
-
47
-
-
34447503592
-
Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease
-
Lam GK, Hummers LK, Woods A, et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007; 34: 1636-1637.
-
(2007)
J Rheumatol
, vol.34
, pp. 1636-1637
-
-
Lam, G.K.1
Hummers, L.K.2
Woods, A.3
-
48
-
-
69949138488
-
An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis
-
Denton CP, Engelhart M, Tvede N, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009; 68: 1433-1439.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1433-1439
-
-
Denton, C.P.1
Engelhart, M.2
Tvede, N.3
-
49
-
-
84878404903
-
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study
-
Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2012; 72: 1217-1220.
-
(2012)
Ann Rheum Dis
, vol.72
, pp. 1217-1220
-
-
Elhai, M.1
Meunier, M.2
Matucci-Cerinic, M.3
-
50
-
-
77956631231
-
Evidence-based management of rapidly progressing systemic sclerosis
-
Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 387-400.
-
(2010)
Best Pract Res Clin Rheumatol
, vol.24
, pp. 387-400
-
-
Khanna, D.1
Denton, C.P.2
-
51
-
-
0142023807
-
Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders
-
Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther 2003; 3: 1041-1049.
-
(2003)
Expert Opin Biol Ther
, vol.3
, pp. 1041-1049
-
-
Tyndall, A.1
Matucci-Cerinic, M.2
-
52
-
-
0035017415
-
Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease
-
Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584.
-
(2001)
Ann Rheum Dis
, vol.60
, pp. 577-584
-
-
Binks, M.1
Passweg, J.R.2
Furst, D.3
-
53
-
-
3242658935
-
Autologous stem cell transplantation in the treatment of systemic sclerosis: Report from the EBMT/EULAR Registry
-
Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63: 974-981.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 974-981
-
-
Farge, D.1
Passweg, J.2
van Laar, J.M.3
-
54
-
-
34548013337
-
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term follow-up of the US multicenter pilot study
-
Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388-1396.
-
(2007)
Blood
, vol.110
, pp. 1388-1396
-
-
Nash, R.A.1
McSweeney, P.A.2
Crofford, L.J.3
-
55
-
-
84875236160
-
The ASTIS trial: Autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results
-
Van Laar JM, Farge D, Sont JK, et al. The ASTIS trial: autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results. Ann Rheum Dis 2012; 71: 151.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 151
-
-
van Laar, J.M.1
Farge, D.2
Sont, J.K.3
-
56
-
-
67649671982
-
Pulmonary complications: One of the most challenging complications of systemic sclerosis
-
Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology 2009; 48: iii40-iii44.
-
(2009)
Rheumatology
, vol.48
-
-
Wells, A.U.1
Steen, V.2
Valentini, G.3
-
57
-
-
34249886274
-
Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis
-
Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging 2007; 22: 120-124.
-
(2007)
J Thorac Imaging
, vol.22
, pp. 120-124
-
-
Shah, R.M.1
Jimenez, S.2
Wechsler, R.3
-
58
-
-
0037098050
-
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome
-
Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
-
(2002)
Am J Respir Crit Care Med
, vol.165
, pp. 1581-1586
-
-
Bouros, D.1
Wells, A.U.2
Nicholson, A.G.3
-
59
-
-
2642535906
-
Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis
-
Yanaba K, Hasegawa M, Takehara K, et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31: 1112-1120.
-
(2004)
J Rheumatol
, vol.31
, pp. 1112-1120
-
-
Yanaba, K.1
Hasegawa, M.2
Takehara, K.3
-
60
-
-
37849030474
-
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease
-
Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91-98.
-
(2008)
Am J Respir Crit Care Med
, vol.177
, pp. 91-98
-
-
Strange, C.1
Bolster, M.B.2
Roth, M.D.3
-
61
-
-
78449269444
-
The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease
-
Wells AU. The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev 2010; 19: 237-241.
-
(2010)
Eur Respir Rev
, vol.19
, pp. 237-241
-
-
Wells, A.U.1
-
62
-
-
0021256105
-
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
-
Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
-
(1984)
Chest
, vol.85
, pp. 751-758
-
-
Mahler, D.A.1
Weinberg, D.H.2
Wells, C.K.3
-
63
-
-
0018119862
-
Scleroderma (progressive systemic sclerosis) progress and course based on a personal series of 118 cases
-
Barnett AJ. Scleroderma (progressive systemic sclerosis) progress and course based on a personal series of 118 cases. Med J Aust 1978; 2: 129-134.
-
(1978)
Med J Aust
, vol.2
, pp. 129-134
-
-
Barnett, A.J.1
-
64
-
-
0021867044
-
The effect of D-penicillamine on pulmonary findings in systemic sclerosis
-
Steen VD, Owens GR, Redmond C, et al. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 28: 882-888.
-
(1985)
Arthritis Rheum
, vol.28
, pp. 882-888
-
-
Steen, V.D.1
Owens, G.R.2
Redmond, C.3
-
65
-
-
0031691662
-
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease
-
Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114: 801-807.
-
(1998)
Chest
, vol.114
, pp. 801-807
-
-
Greidinger, E.L.1
Flaherty, K.T.2
White, B.3
-
66
-
-
77956477550
-
Predictors of interstitial lung disease in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort
-
Assassi S, Sharif R, Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
-
(2010)
Arthritis Res Ther
, vol.12
-
-
Assassi, S.1
Sharif, R.2
Lasky, R.E.3
-
67
-
-
33747894351
-
Scleroderma lung: Initial forced vital capacity as predictor of pulmonary function decline
-
Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602.
-
(2006)
Arthritis Rheum
, vol.55
, pp. 598-602
-
-
Plastiras, S.C.1
Karadimitrakis, S.P.2
Ziakas, P.D.3
-
68
-
-
80053479089
-
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease
-
Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease. Arthritis Rheum 2011; 63: 3078-3085.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 3078-3085
-
-
Khanna, D.1
Tseng, C.H.2
Farmani, N.3
-
69
-
-
44449152061
-
Interstitial lung disease in systemic sclerosis: A simple staging system
-
Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-1254.
-
(2008)
Am J Respir Crit Care Med
, vol.177
, pp. 1248-1254
-
-
Goh, N.S.1
Desai, S.R.2
Veeraraghavan, S.3
-
70
-
-
84874106886
-
Immunosuppression for interstitial lung disease in systemic sclerosis-novel insights and opportunities for translational research
-
Canadian Scleroderma Research Group
-
Hudson M, Steele R, Canadian Scleroderma Research Group, et al. Immunosuppression for interstitial lung disease in systemic sclerosis-novel insights and opportunities for translational research. J Cell Commun Signal 2012; 6: 187-190.
-
(2012)
J Cell Commun Signal
, vol.6
, pp. 187-190
-
-
Hudson, M.1
Steele, R.2
-
71
-
-
80052334244
-
Predicting treatment outcomes and responder subsets in sclerodermarelated interstitial lung disease
-
Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in sclerodermarelated interstitial lung disease. Arthritis Rheum 2011; 63: 2797-2808.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 2797-2808
-
-
Roth, M.D.1
Tseng, C.H.2
Clements, P.J.3
|